OA11400A - Solid oral dosage form comprising a combination ofmetformin and glibenclamide. - Google Patents

Solid oral dosage form comprising a combination ofmetformin and glibenclamide. Download PDF

Info

Publication number: OA11400A
Authority: OA; OAPI
Prior art keywords: glibenclamide; dosage form; oral dosage; metformin; solid oral
Prior art date: 1998-07-15

Application number

OA1200000076A

Other languages

English (en)

Inventor

Yves Bonhomme

Geoffrey Nicholson

Gillian Cave

Sarah J Nicholson

Original Assignee

Lipha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-15

Filing date

2000-03-15

Publication date

2004-04-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-15 Application filed by Lipha filed Critical Lipha

2004-04-08 Publication of OA11400A publication Critical patent/OA11400A/en

Links

ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title claims abstract description 25
229960004580 glibenclamide Drugs 0.000 title claims abstract description 24
239000007787 solid Substances 0.000 title claims description 13
239000006186 oral dosage form Substances 0.000 title claims description 12
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 36
229960003105 metformin Drugs 0.000 claims abstract description 26
239000002245 particle Substances 0.000 claims abstract description 25
239000000203 mixture Substances 0.000 claims description 29
239000008187 granular material Substances 0.000 claims description 15
238000002156 mixing Methods 0.000 claims description 3
238000005550 wet granulation Methods 0.000 claims description 2
238000009472 formulation Methods 0.000 description 16
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 10
229960004329 metformin hydrochloride Drugs 0.000 description 9
238000012360 testing method Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
229920002785 Croscarmellose sodium Polymers 0.000 description 6
239000002775 capsule Substances 0.000 description 5
229960001681 croscarmellose sodium Drugs 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
-1 such ashydrochloride Chemical compound 0.000 description 4
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000013066 combination product Substances 0.000 description 2
229940127555 combination product Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
229940127017 oral antidiabetic Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004110 gluconeogenesis Effects 0.000 description 1
229940095884 glucophage Drugs 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229960002277 tolazamide Drugs 0.000 description 1
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200000076A 1998-07-15 2000-03-15 Solid oral dosage form comprising a combination ofmetformin and glibenclamide. OA11400A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98401781A EP0974356B1 (fr)	1998-07-15	1998-07-15	Comprimés contenant une combinaison de glibenclamide et de metformine

Publications (1)

Publication Number	Publication Date
OA11400A true OA11400A (en)	2004-04-08

Family

ID=8235441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000076A OA11400A (en)	1998-07-15	2000-03-15	Solid oral dosage form comprising a combination ofmetformin and glibenclamide.

Country Status (27)

Country	Link
US (2)	US6303146B1 (fr)
EP (4)	EP0974356B1 (fr)
JP (2)	JP2002520371A (fr)
KR (2)	KR20040053177A (fr)
CN (2)	CN1486698A (fr)
AP (1)	AP1450A (fr)
AR (2)	AR013052A1 (fr)
AT (1)	ATE250418T1 (fr)
AU (2)	AU753604B2 (fr)
BR (1)	BR9906600A (fr)
CA (1)	CA2303537C (fr)
DE (1)	DE69818444T2 (fr)
DK (1)	DK0974356T3 (fr)
DZ (1)	DZ2846A1 (fr)
ES (1)	ES2206868T3 (fr)
ID (1)	ID25784A (fr)
MA (1)	MA24930A1 (fr)
MY (1)	MY129552A (fr)
NZ (1)	NZ503248A (fr)
OA (1)	OA11400A (fr)
PT (1)	PT974356E (fr)
RU (2)	RU2286788C2 (fr)
SI (1)	SI0974356T1 (fr)
TW (2)	TWI245632B (fr)
UY (1)	UY25611A1 (fr)
WO (1)	WO2000003742A2 (fr)
ZA (1)	ZA200001159B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040081697A1 (en) *	1998-11-12	2004-04-29	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) *	1998-11-12	2004-05-27	Smithkline Beecham Corporation	Novel method of treatment
KR20070089259A (ko) *	1999-11-03	2007-08-30	브리스톨-마이어스스퀴브컴파니	메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
US6586438B2 (en) *	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
US20010036479A1 (en)	2000-01-14	2001-11-01	Gillian Cave	Glyburide composition
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) *	2000-11-22	2004-02-06	Lipha	Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
EP1738751B1 (fr) *	2001-01-12	2011-05-11	Sun Pharma Advanced Research Company Ltd	système de libération espacée de médicaments
FR2825023B1 (fr) *	2001-05-23	2005-04-15	Flamel Tech Sa	Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7767249B2 (en) *	2001-06-07	2010-08-03	Hewlett-Packard Development Company, L.P.	Preparation of nanoparticles
US20050271737A1 (en) *	2001-06-07	2005-12-08	Chinea Vanessa I	Application of a bioactive agent to a substrate
US8206753B2 (en) *	2001-06-20	2012-06-26	Metaproteomics, Llc	Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
WO2003011308A1 (fr) *	2001-07-30	2003-02-13	Mitsubishi Pharma Corporation	Medicaments destines a l'amelioration de l'hyperglycemie post-prandiale
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) *	2001-11-29	2003-05-29	Menarini Int Operations Lu Sa	Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
DE60219963T2 (de) *	2002-01-25	2008-02-07	Laboratorios Silanes, S.A. De C.V.	Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird
WO2003072089A1 (fr) *	2002-02-21	2003-09-04	Biovail Laboratories Inc.	Formes posologiques a liberation controlee
US20030187074A1 (en) *	2002-03-04	2003-10-02	Javed Hussain	Oral compositions for treatment of diabetes
US20030219482A1 (en) *	2002-03-21	2003-11-27	Chaudhari Sunil Sudhakar	Multiparticulate compositions for once-a-day administration
WO2003084518A2 (fr)	2002-04-09	2003-10-16	Flamel Technologies	Suspension orale de microcapsules de principes actifs
ES2314227T7 (es)	2002-04-09	2012-11-19	Flamel Technologies	Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
EP1515701B1 (fr)	2002-06-17	2014-09-17	Inventia Healthcare Private Limited	Procédé de fabrication de comprimés multicouches comprenant de la thiazolidinedione et du biguanide
US7445796B2 (en) *	2002-08-19	2008-11-04	L. Perrigo Company	Pharmaceutically active particles of a monomodal particle size distribution and method
CN1729005A (zh) *	2002-11-15	2006-02-01	兰贝克赛实验室有限公司	含双胍－磺酰脲类组合的药物剂型
FR2853831A1 (fr) *	2003-03-05	2004-10-22	Usv Ltd	Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
US7662366B2 (en) *	2003-04-15	2010-02-16	Chugai Seiyaku Kabushiki Kaisha	Method of preventing β cell disruption in pancreatic Langerhans' islets
US20060121108A1 (en) *	2004-12-02	2006-06-08	Prasad C K	System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) *	2004-12-29	2007-10-10	三九医药股份有限公司	格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) *	2004-12-31	2007-10-04	한미약품 주식회사	당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
PE20061245A1 (es) *	2005-03-30	2007-01-06	Generex Pharm Inc	Composiciones para la transmision transmucosa oral de la metformina
US8529537B2 (en) *	2005-08-05	2013-09-10	Kimberly-Clark Worldwide, Inc.	Absorbent article with enclosures
MXPA05009633A (es) *	2005-09-08	2007-03-07	Silanes Sa De Cv Lab	Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
AU2007265475B2 (en)	2006-06-26	2010-08-19	Amgen Inc.	Methods for treating atherosclerosis
WO2008062273A2 (fr) *	2006-11-20	2008-05-29	Cadila Pharmaceuticals Limited	Forme posologique solide administration orale contenant une combinaison de médicaments antidiabétiques
CN101801351B (zh)	2007-07-19	2012-12-12	武田药品工业株式会社	包含阿格列汀和盐酸二甲双胍的固体制剂
PT2489731E (pt)	2007-07-26	2014-09-15	Amgen Inc	Enzimas aciltransferase de lecitina-colesterol modificadas
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
WO2011135106A1 (fr) *	2010-04-26	2011-11-03	Smart Pharma Solutions, S.L	Granulé hautement dispersible pour la préparation de formulations de substances actives de hautes doses et procédé d'obtention de celui-ci
RU2451506C1 (ru)	2011-06-02	2012-05-27	Сергей Юрьевич Лешков	Комбинация для лечения сахарного диабета и его осложнений
WO2013086443A1 (fr)	2011-12-08	2013-06-13	Amgen Inc.	Protéines agonistes de liaison à l'antigène lcat humain et leur utilisation thérapeutique
EP2790729A4 (fr) *	2011-12-12	2015-08-12	Orbis Biosciences Inc	Formulations de particules à libération prolongée
CN104127424A (zh) *	2014-07-30	2014-11-05	沈阳药科大学	格列本脲衍生物及其制备方法和应用
CN105030793A (zh) *	2015-08-25	2015-11-11	瑞阳制药有限公司	二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (fr) *	2017-10-03	2019-04-11	Infinite Clinical Research International, S.A. De C.V.	Triconjugués pour le traitement du diabète sucré
JP2023528726A (ja)	2020-04-01	2023-07-06	ハンジョウジョンメイフアドンファーマシューティカルシーオー．，エルティーディー．	Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
EP4130005A4 (fr)	2020-04-01	2024-04-24	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	Forme cristalline a d'antagoniste du récepteur glp-1 et son procédé de préparation
KR102484756B1 (ko) *	2020-11-13	2023-01-06	한국생산기술연구원	용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) *	2020-12-30	2021-07-23	成都恒瑞制药有限公司	一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE362704C (de) *	1921-08-09	1922-11-02	Naamlooze Vennootschap Interna	Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US4060634A (en) *	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
DE2348334C2 (de)	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en)	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de)	1988-10-01	1991-09-12	Hoechst Ag	Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) *	1989-02-06	1995-04-19	Zeneca Ltd	Phenylsulphone derivatives
GB9016978D0 (en) *	1990-08-02	1990-09-19	Ici Plc	Acetamide derivatives
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DE4323636A1 (de)	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) *	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
KR20060105005A (ko)	1997-06-18	2006-10-09	스미스클라인비이참피이엘시이	티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US6544564B1 (en) *	2001-11-27	2003-04-08	Michael Donald Farley	Cytotoxic pharmaceutical composition

1998
- 1998-07-15 ES ES98401781T patent/ES2206868T3/es not_active Expired - Lifetime
- 1998-07-15 AT AT98401781T patent/ATE250418T1/de not_active IP Right Cessation
- 1998-07-15 PT PT98401781T patent/PT974356E/pt unknown
- 1998-07-15 DK DK98401781T patent/DK0974356T3/da active
- 1998-07-15 SI SI9830517T patent/SI0974356T1/xx unknown
- 1998-07-15 DE DE69818444T patent/DE69818444T2/de not_active Revoked
- 1998-07-15 EP EP98401781A patent/EP0974356B1/fr not_active Revoked
1999
- 1999-07-12 EP EP04008415A patent/EP1435240A3/fr not_active Ceased
- 1999-07-12 JP JP2000559876A patent/JP2002520371A/ja active Pending
- 1999-07-12 KR KR10-2004-7005583A patent/KR20040053177A/ko not_active Ceased
- 1999-07-12 AP APAP/P/2000/001757A patent/AP1450A/en active
- 1999-07-12 EP EP99940114A patent/EP1011684A2/fr not_active Ceased
- 1999-07-12 BR BR9906600-9A patent/BR9906600A/pt not_active Application Discontinuation
- 1999-07-12 NZ NZ503248A patent/NZ503248A/xx not_active IP Right Cessation
- 1999-07-12 WO PCT/EP1999/005571 patent/WO2000003742A2/fr not_active Ceased
- 1999-07-12 RU RU2003126257/15A patent/RU2286788C2/ru active
- 1999-07-12 AU AU54179/99A patent/AU753604B2/en not_active Expired
- 1999-07-12 EP EP10185329A patent/EP2269613A3/fr not_active Ceased
- 1999-07-12 RU RU2000109583/15A patent/RU2226396C2/ru active
- 1999-07-12 CA CA002303537A patent/CA2303537C/fr not_active Expired - Lifetime
- 1999-07-12 ID IDW20000482D patent/ID25784A/id unknown
- 1999-07-12 CN CNA031092314A patent/CN1486698A/zh active Pending
- 1999-07-12 CN CNB998013625A patent/CN1146427C/zh not_active Expired - Lifetime
- 1999-07-12 KR KR10-2000-7002714A patent/KR100478347B1/ko not_active Expired - Lifetime
- 1999-07-13 MA MA25681A patent/MA24930A1/fr unknown
- 1999-07-14 US US09/353,141 patent/US6303146B1/en not_active Expired - Lifetime
- 1999-07-14 TW TW092113257A patent/TWI245632B/zh not_active IP Right Cessation
- 1999-07-14 MY MYPI99002968A patent/MY129552A/en unknown
- 1999-07-14 TW TW088111959A patent/TW555560B/zh not_active IP Right Cessation
- 1999-07-14 DZ DZ990146A patent/DZ2846A1/fr active
- 1999-07-15 UY UY25611A patent/UY25611A1/es not_active Application Discontinuation
- 1999-07-15 AR ARP990103470A patent/AR013052A1/es not_active Application Discontinuation
2000
- 2000-03-07 ZA ZA200001159A patent/ZA200001159B/xx unknown
- 2000-03-15 OA OA1200000076A patent/OA11400A/en unknown
2002
- 2002-12-27 US US10/329,426 patent/USRE38629E1/en not_active Expired - Lifetime
2003
- 2003-03-31 JP JP2003094873A patent/JP2003292443A/ja active Pending
- 2003-11-11 AU AU2003261560A patent/AU2003261560A1/en not_active Abandoned
2008
- 2008-04-07 AR ARP080101435A patent/AR065970A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR9906600A (pt)	2000-07-18
USRE38629E1 (en)	2004-10-19
JP2002520371A (ja)	2002-07-09
MA24930A1 (fr)	2000-04-01
RU2286788C2 (ru)	2006-11-10
ID25784A (id)	2000-11-02
JP2003292443A (ja)	2003-10-15
EP0974356A1 (fr)	2000-01-26
ES2206868T3 (es)	2004-05-16
EP2269613A2 (fr)	2011-01-05
ATE250418T1 (de)	2003-10-15
AP1450A (en)	2005-07-25
CN1486698A (zh)	2004-04-07
TW200303208A (en)	2003-09-01
CA2303537C (fr)	2005-12-06
EP1435240A3 (fr)	2009-08-12
KR20010030603A (ko)	2001-04-16
RU2003126257A (ru)	2005-02-27
EP2269613A3 (fr)	2012-10-17
AP2000001757A0 (en)	2000-03-31
EP0974356B1 (fr)	2003-09-24
CN1275082A (zh)	2000-11-29
NZ503248A (en)	2002-09-27
ZA200001159B (en)	2001-05-31
AR065970A2 (es)	2009-07-15
KR100478347B1 (ko)	2005-03-23
PT974356E (pt)	2004-02-27
AU753604B2 (en)	2002-10-24
CN1146427C (zh)	2004-04-21
EP1011684A2 (fr)	2000-06-28
MY129552A (en)	2007-04-30
DE69818444D1 (de)	2003-10-30
EP1435240A2 (fr)	2004-07-07
TW555560B (en)	2003-10-01
US6303146B1 (en)	2001-10-16
TWI245632B (en)	2005-12-21
WO2000003742A3 (fr)	2000-04-20
DK0974356T3 (da)	2003-10-27
RU2226396C2 (ru)	2004-04-10
SI0974356T1 (en)	2003-12-31
WO2000003742A2 (fr)	2000-01-27
UY25611A1 (es)	2000-08-21
AR013052A1 (es)	2000-11-22
DE69818444T2 (de)	2004-05-06
AU2003261560A1 (en)	2005-05-26
DZ2846A1 (fr)	2003-12-01
KR20040053177A (ko)	2004-06-23
CA2303537A1 (fr)	2000-01-27
AU5417999A (en)	2000-02-07

Publication	Publication Date	Title
OA11400A (en)	2004-04-08	Solid oral dosage form comprising a combination ofmetformin and glibenclamide.
EP0305051B1 (fr)	1993-05-05	Formulation orale d'acétaminophène avec libération étalée et procédé pour la préparer
EP1275391B1 (fr)	2011-03-30	Composition pharmaceutique contenant de l'irbesartan et un diurétique
EP0173210B1 (fr)	1990-05-16	Préparation sous forme de pellet
DE20220415U1 (de)	2003-10-09	Tamsulosin-Tabletten
CN114712359A (zh)	2022-07-08	一种马来酸阿伐曲泊帕药物制剂及其制备方法和应用
AU2014295100B2 (en)	2019-01-03	Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
WO2007011349A1 (fr)	2007-01-25	Nouveau procede de granulation et granule produit par ce procede
US20070014854A1 (en)	2007-01-18	Novel granulation process
US20070014864A1 (en)	2007-01-18	Novel pharmaceutical granulate
EP2179725A1 (fr)	2010-04-28	Composition pharmaceutique comprenant du lévétiracetam
GR1009644B (el)	2019-11-12	Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
JP2000516601A (ja)	2000-12-12	水溶性化合物及びセルロースを含有する粒状物
OA12714A (en)	2006-06-27	Solid oral dosage form comprising a combination ofmetformin and glibenclamide.
CN112022827B (zh)	2023-03-31	一种盐酸赛庚啶快速释放药物制剂及其制备方法
WO2004069229A1 (fr)	2004-08-19	Medicaments antidiabetiques a double liberation et procede de production de ceux-ci
KR20120134545A (ko)	2012-12-12	안정성 및 함량 균일성이 개선된 속방성 약학 조성물의 제조방법
WO2004091587A1 (fr)	2004-10-28	Liberation multiple de medicaments anti-diabete et procede de production associe
Avadhuta Pragathi et al.	2025	FORMULATION AND EVALUATION OF VALSARTAN SR MATRIX TABLETS
MXPA00002568A (en)	2001-11-21	Solid oral dosage form comprising a combination of metformin and glibenclamide
HK1002384B (en)	2004-03-05	Pharmaceutical compositions containing irbesartan